IMMUNITYBIO, INC. Contingent Consideration Classified as Equity, Fair Value Disclosure
IMMUNITYBIO, INC. (IBRX) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $972.00 thousand as of 2020-12-31, per its 8-K/A filed 2021-04-22.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2021-04-22
- 2020-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $972.00K.
- 2019-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $1.73M.
- 2018-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $1.00M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2020-12-31 | $972.00K 8-K/A · filed 2021-04-22 |
| 2019-12-31 | $1.73M 8-K/A · filed 2021-04-22 |
| 2018-12-31 | $1.00M 8-K/A · filed 2021-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |